4basebio Plc Director/PDMR Shareholding

 
TIDM4BB 
 
16 June 2022 
 
                                 4basebio plc 
                                (the "Company") 
 
 
                              Director's Dealings 
 
4basebio PLC (AIM: 4BB), the specialist life sciences group focused on 
exploiting intellectual property in the field of cell and gene therapies and 
DNA vaccines, announces that it was today notified that, on 16 June 2022, David 
Roth, chief financial officer, acquired 5,000 ordinary shares at a price of 430 
pence per share. 
 
As a result of the acquisition of ordinary shares, David Roth's beneficial 
holding comprises 317,000 ordinary shares representing approximately 2.6 per 
cent. of the Company's issued share capital. 
 
This announcement contains inside information for the purposes of Article 7 of 
EU Regulation 596/2014. 
 
For further enquiries, please contact: 
 
4basebio plc                                            [phone] 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated                 [phone] 
Adviser) 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker)                                    [phone] 
 
Geoff Nash/Richard Chambers/Charlotte 
Sutcliffe 
 
 
Notification and public disclosure of transactions by persons discharging 
managerial responsibilities and persons closely associated with them 
 
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 
596/2014 
 
 1. Details of the person discharging managerial responsibilities/person 
    closely associated 
 
 a. Name 
 
David Roth 
 
 1. Reason for notification 
 
 a. Position/Status 
 
Chief Financial Officer 
 
 a. Initial notification/ Amendment          Initial 
 
 1. Details of the issuer, emission allowance market participant, auction 
    platform, auctioneer or auction monitor 
 
 a. Name                                       4basebio plc 
 
 a. LEI                                           213800E2DX9EAIUNCB30 
 
 1. Details of the transaction(s): section to be repeated for (i) each type of 
    instrument; (ii) each type of transaction; (iii) each date; and (iv) each 
    place where transactions have been conducted 
 
 a. Description of the financial instrument, type Ordinary Shares of instrument 
 
    Identification Code                       ISIN: GB00BMCLYF79 
 
 b. Nature of the transaction               Acquisition of ordinary shares 
 
 c. Price(s) and volume(s)               Volume(s)               Price (p) 
 
 
5,000430p 
 
 a. Aggregated information 
 
 
- Aggregated Volume 5,000 
- Price430 pence per share 
 
 
 
 
 a. Date of the transaction               16/06/2022 
 
 b. Place of the transaction London Stock Exchange, AIM 
 
 
 
END 
 
 

(END) Dow Jones Newswires

June 16, 2022 10:28 ET (14:28 GMT)